bioRxiv Science⌕ Search

bioRxiv · 10.64898/2025.12.13.694153

A Model for the Diversity Explosion Fundamental to Metastasis

Abstract

Most deaths from cancer are caused by their metastases. Along with the ability to evade the immune system and to invade and disrupt very different tissue environments, metastases usually develop resistance to whatever therapeutic approaches are tried. Their extreme adaptability requires a diversity of traits from which natural selection can choose, but current models, such as the epithelial-to-mesenchymal transition (EMT), do not directly address how this diversity is generated. We observed that single cell clones of Panc1 human pancreas cancer cells that had had crispR knock outs (KO) of the gene for activin-like kinase 4 (ALK4) had developed a markedly diverse morphology. Time-lapse and fluorescence microscopy, FACS analysis and mitotic chromosome squashes provided evidence that the cells diversify profoundly in size, behavior and chromosome number. This diversity appears to develop through cytokinesis failure, the generation of very large multinuclear cells that exhibit a high range of nuclear configurations, coupled with continued cell divisions that sometimes generate three, four, and more daughter cells in one cell division. This astounding activity often resulted in cells that were much smaller than the normal Panc1 cells, and indirect evidence suggests they were significantly sub-ploidy, yet underwent regular cell divisions. A subset of the smaller cells were highly motile, and were observed to sometimes merge together or even into larger cells. This phenomenon could provide an unappreciated venue for transferring mutated genes, chromosome fragments, whole chromosomes or sets of chromosomes into an invaded cell. We suggest that these observations may be a serendipitous illustration of the missing link between the genetic mutations implicated in the development of primary carcinoma, and the extreme genomic diversity that characterizes malignant metastases. Graphical SummarySingle cell clones of Panc 1 ALK4 KO cultures changed from largely uniformly epithelioid in character (A) to cultures composed of an unexpectedly wide variety of cells, and that this variety is not explained by the traditional "EMT" (epithelial-to-mesenchymal-transition). These cells range from very small to very large, have varying degrees of motility, chromosome number, and cell division behavior. We describe the new morphologies and behaviors, and present time lapse movies and microscopic evidence that help explain the evolution of this variety. These new cell types integrate into colonies where the smallest cells gather into spherical masses (D). We believe that the heterogeneity in genomic content and behavior provides the variety needed for natural selection to select cells that are resistant to most treatments for metastatic cancers.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

O'Brien, E. T.. 2025-12-16. A Model for the Diversity Explosion Fundamental to Metastasis. https://doi.org/10.64898/2025.12.13.694153

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression

Both nuclear pore complexes (NPCs) and RNA N6-methyladenosine (m6A) machinery are indispensable for proper cellular function. Although their collaborative roles in the nuclear export of messenger RNAs (mRNAs) have been reported, it remains ambiguous whether and how this collaboration may contribute to cancer progression. Here we identify a functional cooperation between NPCs and m6A signaling that promotes the development of castration-resistant prostate cancer (CRPC). We showed that nuclear export of m6A-modified mRNAs, mediated by the interaction between RNA methyltransferase METTL3 and the nucleoporin NUP93, is functionally coupled to cholesterol biosynthesis. Given that cholesterol-fueled intratumoral androgen production is one of the mechanisms driving CRPC, we demonstrated that overexpression of the wild-type METTL3 or NUP93, but neither the enzymatically dead METTL3 nor the mutant NUP93 that loses METTL3-interacting capability, elevates intracellular levels of androgens, activates AR signaling under castrate condition, and promotes androgen-independent growth of prostate cancer cells both in vitro and in vivo. Importantly, pharmacological inhibition of METTL3 or targeted demethylation on mRNAs encoding key cholesterol biosynthesis enzymes effectively suppressed CRPC malignancy. Together, these findings uncover a therapeutically targetable m6A-METTL3-NUP93 axis that links nuclear mRNA export and metabolic reprogramming to fuel CRPC progression, providing a conceptually new strategy for the treatment of this lethal disease.

cancer biology↗

ST6Gal2 promotes α2,6-sialylation and aggressive phenotypes in neuroblastoma cells

Neuroblastoma is the most common extracranial solid tumor of childhood. Its clinical behavior ranges from spontaneous regression to lethal, treatment-refractory disease. Aberrant 2,6-sialylation contributes to aggressive phenotypes in many cancers, but the role of ST6Gal2, a neural-enriched 2,6-sialyltransferase, in neuroblastoma is largely unexplored. Here, we examine the clinical and functional significance of ST6Gal2 in neuroblastoma. In two independent public cohorts (SEQC, n=498; Kocak, n=649), high ST6GAL2 expression was associated with significantly worse overall and event-free survival. In the SEQC cohort, ST6GAL2 expression was higher in high-risk and MYCN-amplified tumors, varied across International Neuroblastoma Staging System stages, and correlated positively with a mesenchymal transcriptional signature (Spearman {rho}=0.181). The mesenchymal correlation was reproduced in the Kocak cohort ({rho}=0.204). Stable shRNA-mediated knockdown of ST6GAL2 in SK-N-AS and SK-N-BE(2) cells reduced proliferation and viability, impaired wound closure, and decreased migration and invasion. In preliminary experiments in SK-N-AS cells, ST6GAL2 knockdown reduced binding of Sambucus nigra agglutinin, consistent with a role for ST6Gal2 in 2,6-sialylation. Together, these findings link ST6Gal2 expression to aggressive clinical and transcriptional features and pro-tumorigenic phenotypes in neuroblastoma and nominate ST6Gal2-mediated sialylation as a candidate pathway for mechanistic study.

cancer biology↗

Unsupervised transcriptomic analysis of paired pre- and post-treatment specimens reveals divergent chemoimmunomodulatory induction trajectories in breast cancer

The immunomodulatory effects of chemotherapy (chemoimmunomodulation; CIM) are clinically consequential and heterogeneous, yet no systematic framework exists for classifying the immunomodulatory trajectory a tumor follows in response to treatment (CIM trajectory). Here, we present the CIM Induction Classifier (CIMIC), an unsupervised clustering pipeline leveraging delta gene expression across 3,189 CIM-related genes to classify specimens chemoimmunomodulatory trajectory. Applied to two pre- and post-chemotherapy breast cancer (BC) datasets (NKI/SMC, N = 36; NEO, N = 19) and nine epirubicin-perturbed triple-negative BC (TNBC) cell lines, CIMIC identified two divergent CIM trajectories: a functional CIM (Fun-CIM) trajectory, broadly conserved across tumors and cell lines and characterized by induction of inflammatory cell death, antigen presentation, viral mimicry, and adaptive immune activation programs, and a dysfunctional CIM (Dys-CIM) trajectory, characterized by induction of proteostatic and metabolic stress-adaptation programs, reduced immune cell abundances and cytotoxic activity, and enrichment of aggressive BC subtypes. Using survival and longitudinal transcriptomic data in NKI/SMC (N = 20), treatment-induced increases in Fun-CIM-associated genes and ssGSEA scores were associated with reduced recurrence, whereas Dys-CIM-associated genes and scores were associated with increased recurrence. In multivariable analyses within independent chemotherapy-treated BC cohorts (METABRIC, N = 412; SCAN-B, N = 2,462), higher baseline Fun-CIM ssGSEA scores were associated with better outcomes, whereas higher baseline Dys-CIM ssGSEA scores were associated with worse outcomes. These findings establish CIM as a dynamic, trajectory-level process and position CIMIC as a framework for defining CIM trajectories and supporting future efforts to identify predictors, mechanisms, and therapeutic strategies that maximize beneficial CIM.

cancer biology↗